Page last updated: 2024-11-08

eprodisate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

eprodisate: slows the decline of renal function in AA amyloidosis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID428573
CHEMBL ID2111092
SCHEMBL ID34216
MeSH IDM0510436

Synonyms (34)

Synonym
1,3-propanedisulfonic acid, 70% in h2o
propane-1,3-disulfonic acid
inchi=1/c3h8o6s2/c4-10(5,6)2-1-3-11(7,8)9/h1-3h2,(h,4,5,6)(h,7,8,9)
mgnvwudmmxzudi-uhfffaoysa-
21668-77-9
1,3-propanedisulfonic acid
eprodisate [inn]
6qfp76v7s7 ,
unii-6qfp76v7s7
eprodisate
propane-1,3-disulfonate
FT-0625314
propane-1,3-disulphonate
eprodisate [who-dd]
SCHEMBL34216
DTXSID4048301
1,3-propanesulfonic acid
MGNVWUDMMXZUDI-UHFFFAOYSA-N
1,3-propanedisulphonic acid
CHEMBL2111092
AKOS025402717
mfcd00191482
D92088
J-014224
1,3-propanedisulfonic acid (50-60% in water)
DB06405
CS-0100921
HY-128849
Q27265336
MS-23104
guanosine-5-triphosphatetetrasodiumsalt
WAA66877
STARBLD0009312
?eprodisate

Research Excerpts

Overview

Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans.

ExcerptReferenceRelevance
"Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues."( Eprodisate for the treatment of renal disease in AA amyloidosis.
Balshaw, R; Butrimiene, I; Dember, LM; Garceau, D; Gorevic, PD; Hauck, W; Hawkins, PN; Hazenberg, BP; Lachmann, HJ; Lesnyak, O; Livneh, A; Merlini, G; Obici, L; Puéchal, X; Skinner, M, 2007
)
2.5

Effects

ExcerptReferenceRelevance
"Eprodisate has possible applicability to other types of amyloidosis; the results of a recent randomized trial showed that it may slow the progression of AA amyloidosis-related renal disease but confirmatory studies are necessary."( Eprodisate in amyloid A amyloidosis: a novel therapeutic approach?
Manenti, L; Tansinda, P; Vaglio, A, 2008
)
2.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (50.00)29.6817
2010's5 (41.67)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.56 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index30.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (15.38%)5.53%
Reviews5 (38.46%)6.00%
Case Studies1 (7.69%)4.05%
Observational0 (0.00%)0.25%
Other5 (38.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]